Literature DB >> 29454927

Syndemics among individuals enrolled in the PrEP Brasil Study.

Raquel B De Boni1, Iona K Machado2, Mauricio T L De Vasconcellos3, Brenda Hoagland1, Esper G Kallas4, José Valdez Madruga5, Nilo M Fernandes1, Natalia B Cerqueira4, Ronaldo I Moreira1, Silvia P Goulart4, Valdilea G Veloso1, Beatriz Grinsztejn1, Paula M Luz6.   

Abstract

BACKGROUND: Concurrent psychosocial problems may synergistically increase the risk of HIV infection (syndemics), representing a challenge for prevention. We aimed to evaluate the prevalence and associated factors of syndemics among men who have sex with men (MSM) and transgender women (TGW) enrolled in the Brazilian pre-exposure prophylaxis demonstration study (PrEP Brasil Study).
METHODS: Secondary cross-sectional analysis of the PrEP Brasil Study was performed. Of 450 HIV-seronegative MSM/TGW enrolled in the PrEP Brasil Study- conducted at Rio de Janeiro and São Paulo, Brazil- 421 participants with complete data were included in the present analysis. Syndemics was defined as occurrence of ≥2 of the following conditions: polysubstance (≥2) use, binge drinking, positive depression screen, compulsive sexual behavior, and intimate partner violence (IPV).
RESULTS: The prevalence of recent polysubstance use was 22.8%, binge drinking 51.1%, positive depression screening 5.2%, compulsive sexual behavior 7.1%, and IPV 7.3%. Syndemics prevalence was 24.2%, and associated factors were younger age (adjusted Odds Ratio (aOR) 0.95, 95% Confidence Interval (95% CI) 0.92-0.98 per year increase), TGW vs. MSM (aOR 3.09, 95% CI: 1.2-8.0), some college education or more vs. less than college (aOR 2.49, 95% CI: 1.31-4.75), and multiple male sexual partners in prior 3 months (aOR 1.69, 95% CI: 0.92-3.14).
CONCLUSION: Given the high prevalence of syndemics, particularly of polysubstance use and binge drinking, PrEP delivery offers an opportunity to diagnose and intervene in mental and social well-being.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Binge drinking; HIV infection; MSM; Polysubstance use; Pre-exposure prophylaxis; Transgender

Mesh:

Year:  2018        PMID: 29454927     DOI: 10.1016/j.drugalcdep.2017.12.016

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  5 in total

1.  Intimate Partner Violence in Transgender Populations: Systematic Review and Meta-analysis of Prevalence and Correlates.

Authors:  Sarah M Peitzmeier; Mannat Malik; Shanna K Kattari; Elliot Marrow; Rob Stephenson; Madina Agénor; Sari L Reisner
Journal:  Am J Public Health       Date:  2020-07-16       Impact factor: 11.561

Review 2.  Integrating HIV and mental health interventions to address a global syndemic among men who have sex with men.

Authors:  Don Operario; Shufang Sun; Amiel Nazer Bermudez; Rainier Masa; Sylvia Shangani; Elise van der Elst; Eduard Sanders
Journal:  Lancet HIV       Date:  2022-06-21       Impact factor: 16.070

3.  Variations in Testing for HIV and Other Sexually Transmitted Infections Across Gender Identity Among Transgender Youth.

Authors:  Akshay Sharma; Erin Kahle; Kieran Todd; Sarah Peitzmeier; Rob Stephenson
Journal:  Transgend Health       Date:  2019-02-20

4.  Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men.

Authors:  Paul A Shuper; Narges Joharchi; Isaac I Bogoch; Mona Loutfy; Frederic Crouzat; Philippe El-Helou; David C Knox; Kevin Woodward; Jürgen Rehm
Journal:  BMC Public Health       Date:  2020-11-25       Impact factor: 3.295

5.  Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxis.

Authors:  Ada Miltz; Fiona Lampe; Sheena McCormack; David Dunn; Ellen White; Alison Rodger; Andrew Phillips; Lorraine Sherr; Ann K Sullivan; Iain Reeves; Amanda Clarke; Mitzy Gafos
Journal:  BMJ Open       Date:  2019-12-10       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.